retosiban
Small moleculeexperimental
Retosiban also known as GSK-221,149-A is an oral drug which acts as an oxytocin receptor antagonist. It is being developed by GlaxoSmithKline for the treatment of preterm labour. Retosiban has high affinity for the oxytocin receptor and has greater than 1400-fold selectivity over the related vasopressin receptors — Wikipedia
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00457925)
Timeline
Indications
Mechanism of action
- Oxytocin receptorANTAGONIST
OXTR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1- Mol. weight
- 494.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRetosiban ↗
- ChEMBLCHEMBL429736 ↗
Also known as
- (3r,6r)-3-indan-2-yl-1-((1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl)-6-((1s)-1-methylpropyl)-2,5-piperazinedione
- gsk221149
- gsk221149
- gsk221149a
- gsk221149a
- gsk221149a
- retosiban
- retosiban
- retosiban
- retosiban
- retosiban
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02377466 | Phase 3 | Feb 29, 2016 | GlaxoSmithKline, PPD |
| NCT02292784 | Phase 3 | Jun 1, 2015 | GlaxoSmithKline, PPD |
| NCT02377414 | Phase 1 | Mar 2, 2015 | GlaxoSmithKline |
| NCT02292771 | Phase 3 | Mar 1, 2015 | GlaxoSmithKline, PPD |
| NCT01867996 | Phase 1 | Jun 11, 2013 | GlaxoSmithKline |
| NCT01702376 | Phase 1 | Oct 3, 2012 | GlaxoSmithKline |
| NCT01627587 | Phase 1 | Dec 12, 2011 | GlaxoSmithKline |
| NCT00404768 | Phase 2 | Oct 12, 2007 | GlaxoSmithKline |
| NCT00449709 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
| NCT00457925 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 3 | 2006 |
| PPD | For profit | 3 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1